Skip to content
You can now search across every topic, entity and event.What's new
American Cancer Society BrightEdge
OrganisationUS

American Cancer Society BrightEdge

ACS-affiliated oncology venture fund; co-invested in CellCentric's £170m Series D.

Last refreshed: 13 May 2026 · Appears in 1 active topic

Timeline for American Cancer Society BrightEdge

View full timeline →
Follow UK Startups and Innovation →
Common Questions
What is the American Cancer Society BrightEdge fund?
BrightEdge is the American Cancer Society's impact-investing Arm, funding for-profit biotech aligned with reducing cancer burden, including co-investment in CellCentric's inobrodib multiple myeloma programme.Source: American Cancer Society
Why is a cancer charity investing in biotech startups?
The American Cancer Society's BrightEdge vehicle invests in oncology biotech to accelerate cancer treatments aligned with its mission, providing capital and patient advocacy infrastructure alongside financial returns.Source: Lowdown uk-startups-and-innovation U#4
What drugs is CellCentric developing?
CellCentric is developing inobrodib, a first-in-class p300/CBP histone acetyltransferase inhibitor targeting relapsed multiple myeloma and castrate-resistant prostate cancer.Source: Lowdown uk-startups-and-innovation U#4

Background

American Cancer Society BrightEdge participated in CellCentric's £170m Series D in May 2026 alongside Venrock Healthcare Capital Partners, Pfizer, Fidelity, Sofinnova Partners, and others. CellCentric's inobrodib targets multiple myeloma and prostate cancer — disease areas central to the ACS mission.

American Cancer Society BrightEdge is the impact-investing and venture Arm of the American Cancer Society, one of the largest cancer patient advocacy and research funding organisations in the US. BrightEdge invests in for-profit biotech and oncology companies that align with the ACS's mission to reduce cancer burden. As a mission-aligned investor rather than purely financial vehicle, BrightEdge's participation validates the clinical potential of CellCentric's programme while providing the company with access to ACS's patient advocacy networks and clinical trial recruitment infrastructure in the US.